Peijie Hou

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

Life Sciences, Immunology, Oncology +14

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Meagan P. O’Brien, Eduardo Forleo‐Neto, Bret J. Musser et al. · New England Journal of Medicine · 2021 · 480 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Justin F. Gainor, Manish R. Patel, Jeffrey S. Weber et al. · Cancer Discovery · 2024 · 100 citations

Medicine, Immunology, Oncology +17

Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Maja Di Rocco, Eduardo Forleo‐Neto, Robert J. Pignolo et al. · Nature Medicine · 2023 · 53 citations · Full text

Medicine, Pathology, Bone Scintigraphy +9

Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

Adnan Khattak, Matteo S. Carlino, Tarek Meniawy et al. · Cancer Research · 2023 · 49 citations

Life Sciences, Immunology, Oncology +17